| Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities |
83 |
| Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues |
48 |
| Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications |
48 |
| Circular RNAs: The star molecules in cancer |
43 |
| Cellular and molecular mechanisms of kidney fibrosis |
41 |
| Flavonoids and the gastrointestinal tract: Local and systemic effects |
34 |
| New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration |
32 |
| ROS signaling and ER stress in cardiovascular disease |
32 |
| Benefits of the Mediterranean diet: Epidemiological and molecular aspects |
31 |
| MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance |
31 |
| The PDGF/PDGFR pathway as a drug target |
31 |
| Circulating biomarkers for early detection and clinical management of colorectal cancer |
30 |
| Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential |
29 |
| Single-cell RNA sequencing: Technical advancements and biological applications |
29 |
| Identifying cell populations with scRNASeq |
29 |
| Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: Insights into the pathophysiology of lung diseases |
26 |
| Subpopulations of extracellular vesicles and their therapeutic potential |
25 |
| Berry anthocyanin intake and cardiovascular health |
25 |
| Developmental pathways in the pathogenesis of lung fibrosis |
23 |
| Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection |
23 |
| Exosomes and cardioprotection - A critical analysis |
21 |
| PDGF in organ fibrosis |
21 |
| Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action |
20 |
| Lifestyle and dietary environmental factors in colorectal cancer susceptibility |
19 |
| Absorption, metabolism, distribution and excretion of (-)-epicatechin: A review of recent findings |
19 |
| Brain docosahexaenoic acid uptake and metabolism |
19 |
| Oxidative stress in chronic lung disease: From mitochondrial dysfunction to dysregulated redox signaling |
19 |
| Omega-3 fatty acids and adipose tissue biology |
18 |
| Extracellular vesicles in obesity and diabetes mellitus |
18 |
| Emerging role of extracellular vesicles in musculoskeletal diseases |
18 |
| Update on genetic predisposition to colorectal cancer and polyposis |
17 |
| Intestinal fibrosis |
16 |
| Mechanisms of dietary flavonoid action in neuronal function and neuroinflammation |
16 |
| Many tocopherols, one vitamin E |
16 |
| Extracellular vesicles: Novel mediator for cell to cell communications in liver pathogenesis |
16 |
| Plant bioactives and redox signaling: (-)-Epicatechin as a paradigm |
15 |
| N-Docosahexaenoylethanolamine: A neurotrophic and neuroprotective metabolite of docosahexaenoic |
15 |
| Redox control in cancer development and progression |
15 |
| PDGF-C and PDGF-D signaling in vascular diseases and animal models |
14 |
| Extracellular vesicles compartment in liquid biopsies: Clinical application |
14 |
| Recommending flavanols and procyanidins for cardiovascular health: Revisited |
13 |
| The role of fatty acids and their endocannabinoid-like derivatives in the molecular regulation of appetite |
13 |
| Current concepts of non-coding RNA regulation of immune checkpoints in cancer |
13 |
| Extracellular vesicles in neurodegenerative diseases |
12 |
| The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination |
12 |
| Microfluidic single-cell technology in immunology and antibody screening |
11 |
| Omega-3 fatty acids and leukocyte-endothelium adhesion: Novel anti-atherosclerotic actions |
11 |
| The importance of long non-coding RNAs in neuropsychiatric disorders |
10 |
| FFA4 (GPR120) as a fatty acid sensor involved in appetite control, insulin sensitivity and inflammation regulation |
10 |
| The extensive role of miR-155 in malignant and non-malignant diseases |
10 |
